Venture Partners L P Sofinnova VII's Net Worth

$144 Million

Estimate Recalculated Nov 1, 2024 06:37AM EST

Who is Venture Partners L P Sofinnova VII?

Venture Partners L P Sofinnova VII has an estimated net worth of $144 Million. This is based on reported shares across multiple companies, which include AMARIN CORP PLC\UK, Trius Therapeutics Inc, HYPERION THERAPEUTICS INC, AERIE PHARMACEUTICALS INC, Durata Therapeutics, Inc., and ANESIVA, INC..

SEC CIK

Venture Partners L P Sofinnova VII's CIK is 0001380734

Past Insider Trading and Trends

2010 was Venture Partners L P Sofinnova VII's most active year for acquiring shares with 6 total transactions. Venture Partners L P Sofinnova VII's most active month to acquire stocks was the month of July. 2011 was Venture Partners L P Sofinnova VII's most active year for disposing of shares, totalling 7 transactions. Venture Partners L P Sofinnova VII's most active month to dispose stocks was the month of February. 2010 saw Venture Partners L P Sofinnova VII paying a total of $16,126,140.20 for 7,231,144 shares, this is the most they've acquired in one year. In 2015 Venture Partners L P Sofinnova VII cashed out on 1,939,474 shares for a total of $89,215,804.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

AMARIN CORP PLC\UK (AMRN) Snapshot price: $0.6094

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-4.75%
-424.90K
$7.25
-$3,080,609.98
8.51M
Mar 29
Form 4
-6.05%
-575.10K
$7.55
-$4,341,332.61
8.94M
Mar 24 - Mar 25
Form 4
-17.37%
-2.00M
$7.50
-$15,000,000.00
9.51M
Mar 11
Form 4
-5.24%
-637.00K
$7.26
-$4,622,857.88
11.51M
Mar 9 - Mar 10
Form 4
-2.90%
-363.00K
$8.13
-$2,952,787.20
12.15M
Feb 25
Form 3
—
0
—
—
0
No matching records found

HYPERION THERAPEUTICS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-1.94M
$46.00
-$89,215,804.00
0
May 7
Form 4
-17.72%
-417.75K
$27.70
-$11,571,591.90
1.94M
Jun 4
Form 4
-20.02%
-590.00K
$30.02
-$709,222.50
2.36M
Scheduled
Mar 3 - Mar 4
Form 4
+74,816.65%
2.94M
$10.00
—
2.95M
Jul 31
Form 3
—
0
—
—
0
No matching records found

AERIE PHARMACEUTICALS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-39.15%
-1.01M
$24.91
-$24,208,330.17
1.57M
Jul 9 - Jul 10
Form 4
-6.94%
-191.98K
—
—
2.57M
Jun 2
Form 4
-10.48%
-323.93K
$16.00
-$5,182,912.00
2.77M
May 22
Form 4
∞
3.09M
$6.49
—
3.09M
Oct 25
Form 3
—
0
—
—
0
No matching records found

Durata Therapeutics, Inc. No price found

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+134.95%
2.27M
$9.00
$5,294,124.00
3.95M
Jul 24
Form 3
—
0
—
—
0
No matching records found

Trius Therapeutics Inc No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-96.00%
-3.47M
—
—
144.65K
Scheduled
Jan 12
Form 4/A
∞
3.62M
$4.68
—
3.62M
Aug 6
Form 3/A
—
0
—
—
0
Form 4
∞
3.62M
$4.68
—
3.62M
Aug 6
Form 3
—
0
—
—
0
No matching records found